HRP20210611T1 - Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala - Google Patents
Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala Download PDFInfo
- Publication number
- HRP20210611T1 HRP20210611T1 HRP20210611TT HRP20210611T HRP20210611T1 HR P20210611 T1 HRP20210611 T1 HR P20210611T1 HR P20210611T T HRP20210611T T HR P20210611TT HR P20210611 T HRP20210611 T HR P20210611T HR P20210611 T1 HRP20210611 T1 HR P20210611T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- protofibril
- stabilized
- monomer
- binds
- Prior art date
Links
- 239000000178 monomer Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 claims 4
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102220606690 Neurotrimin_D23N_mutation Human genes 0.000 claims 1
- 102220538768 Superoxide dismutase [Cu-Zn]_E22G_mutation Human genes 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 102200131541 rs121912450 Human genes 0.000 claims 1
- 102200158871 rs33955330 Human genes 0.000 claims 1
- 102220092852 rs754853086 Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Antitijelo, naznačeno time što se antitijelo podiže protiv stabiliziranog protofibrila koji sadrži N-terminalni krnji amiloid beta (Aβ) Aβ3(pE)-42, i odabran je tako da (i) veže topivi protofibril koji sadrži Aβ3(pE)-42, (ii) veže Aβ3(pE)-42 monomer, i (iii) ne pokazuje ili u osnovi nema vezanja s ne-N-terminalnim krnijm Aβ monomerom, pri čemu:
(a) ne-N-terminalni krnji Aβ monomer može ili ne mora imati C-terminalni krnji dio; i
(b) stabilizirani protofibril stabilizira se s hidrofobnim organskim sredstvom koje sadrži neionski deterdžent, cviterionski deterdžent, 4-hidroksi-2-nonenal (HNE) ili 4-okso-2-nonenal (ONE), i pri čemu stabilizirani protofibril ima nižu brzinu stvaranja u netopivi agregirani oblik od ne-stabiliziranog oblika protofibrila.
2. Antitijelo prema zahtjevu 1, naznačeno time što topivi protofibril na koji se antitijelo veže sadrži Aβ koji obuhvaća arktičku mutaciju (E22G), nizozemsku mutaciju (E22Q), talijansku mutaciju (E22K), Iowa mutaciju (D23N) ili flamansku mutaciju (A21G), ili njihove dvije ili više kombinacija.
3. Antitijelo prema zahtjevu 1 ili 2 koje se veže na protofibril koji sadrži najmanje 80% Aβ3(pE)-42 s vrijednošću IC50 manjom ili jednakom 25 nM.
4. Antitijelo prema zahtjevu 3, koje se veže na protofibril koji sadrži 80% Aβ3(pE)-42 i 20% Aβ1-42 s vrijednošću IC50 manjom ili jednakom 25 nM.
5. Antitijelo prema zahtjevu 1 koje se veže na protofibril koji sadrži 100% Aβ3(pE)-42 s IC50 vrijednošću manjom ili jednakom 100 nM.
6. Antitijelo prema bilo kojem od zahtjeva 1-5, naznačeno time što je antitijelo ljudsko, humanizirano ili modificirano da smanji antigenost kod čovjeka, i/ili pri čemu antitijelo ima smanjenu aktivnost komplementa i/ili gdje je antitijelo Fab fragment, npr. F(ab), F (ab)2 ili DiFabody.
7. Antitijelo prema bilo kojem od zahtjeva 1-6, naznačeno time što je antitijelo monoklonsko.
8. Antitijelo prema bilo kojem od zahtjeva 1-7, naznačeno time što antitijelo također veže stabilizirani protofibril.
9. Postupak za otkrivanje protofibrila koji sadrži N-terminalni krnji Aβ3(pE)-42 i za otkrivanje N-terminalnog krnjeg Aβ3(pE)-42 monomera, obuhvaća dodavanje antitijela prema bilo kojem od zahtjeva 1-8 biološkom uzorku koji sadrži ili za koji se sumnja da sadrži protofibril i/ili monomer, i mjere koncentraciju kompleksa nastalog između antitijela i protofibrila i kompleksa nastalog između protutijela i monomera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| EP10739701.0A EP2448968B1 (en) | 2009-06-29 | 2010-06-29 | ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210611T1 true HRP20210611T1 (hr) | 2021-05-28 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210611TT HRP20210611T1 (hr) | 2009-06-29 | 2021-04-16 | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (hr) |
| EP (2) | EP2448968B1 (hr) |
| JP (3) | JP2012532094A (hr) |
| AU (1) | AU2010267640B2 (hr) |
| CA (1) | CA2765602C (hr) |
| CY (1) | CY1124034T1 (hr) |
| DK (1) | DK2448968T3 (hr) |
| ES (1) | ES2864049T3 (hr) |
| HR (1) | HRP20210611T1 (hr) |
| HU (1) | HUE053949T2 (hr) |
| LT (1) | LT2448968T (hr) |
| PL (1) | PL2448968T3 (hr) |
| PT (1) | PT2448968T (hr) |
| SI (1) | SI2448968T1 (hr) |
| WO (1) | WO2011001366A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| NZ567888A (en) | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| BR112013023211B1 (pt) * | 2011-03-16 | 2022-11-08 | Vivoryon Therapeutics N.V. | Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit |
| KR102564384B1 (ko) | 2014-07-10 | 2023-08-07 | 바이오악틱 에이비 | 개선된 Aβ 프로토피브릴 결합 항체 |
| EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| WO2018011353A1 (en) | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
| MX2021000778A (es) | 2018-07-24 | 2021-03-31 | Eisai R&D Man Co Ltd | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. |
| JPWO2021006212A1 (hr) * | 2019-07-08 | 2021-01-14 | ||
| US11339212B2 (en) | 2020-06-26 | 2022-05-24 | Bioarctic Ab | α-synuclein protofibril-binding antibodies |
| WO2023283650A1 (en) | 2021-07-09 | 2023-01-12 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| AU2022338055A1 (en) | 2021-08-30 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| WO2023149970A1 (en) | 2022-02-02 | 2023-08-10 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| EP1200470B1 (en) * | 1999-08-04 | 2004-11-24 | The University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| SG172616A1 (en) * | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP2298807A3 (en) * | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| NZ567888A (en) * | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| CA2705582A1 (en) * | 2007-11-16 | 2009-05-22 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| WO2009133521A2 (en) * | 2008-04-29 | 2009-11-05 | Bioartic Neuroscience Ab | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
-
2010
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en active Application Filing
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-16 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2448968A1 (en) | 2012-05-09 |
| US20230295283A1 (en) | 2023-09-21 |
| WO2011001366A1 (en) | 2011-01-06 |
| AU2010267640B2 (en) | 2015-03-05 |
| CA2765602A1 (en) | 2011-01-06 |
| CY1124034T1 (el) | 2022-05-27 |
| US20120100129A1 (en) | 2012-04-26 |
| HUE053949T2 (hu) | 2021-08-30 |
| EP2448968B1 (en) | 2021-01-27 |
| JP2019218362A (ja) | 2019-12-26 |
| JP2017197531A (ja) | 2017-11-02 |
| PL2448968T3 (pl) | 2021-09-13 |
| JP6884025B2 (ja) | 2021-06-09 |
| ES2864049T3 (es) | 2021-10-13 |
| CA2765602C (en) | 2021-05-25 |
| AU2010267640A1 (en) | 2012-01-19 |
| EP3892633A1 (en) | 2021-10-13 |
| LT2448968T (lt) | 2021-05-10 |
| SI2448968T1 (sl) | 2021-07-30 |
| PT2448968T (pt) | 2021-04-30 |
| DK2448968T3 (da) | 2021-04-12 |
| JP2012532094A (ja) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210611T1 (hr) | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala | |
| TWI549966B (zh) | 測定澱粉樣肽之抗體、套組及方法 | |
| Wang-Dietrich et al. | The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease | |
| JP2009525758A5 (hr) | ||
| JP2007527865A5 (hr) | ||
| WO2007050359A3 (en) | Anti-addl monoclonal antibody and use thereof | |
| DE69940364D1 (de) | Fab Fragmentbibliotheken und Verfahren für deren Verwendung | |
| CR20150669A (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
| WO2006091802A3 (en) | Norbornene-type polymers, compositions thereof and lithographic processes using such compositions | |
| WO2010039873A3 (en) | Humanized endoglin antibodies | |
| WO1998057994A3 (en) | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
| DE69417417D1 (de) | Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen | |
| JP2007525427A5 (hr) | ||
| MX338640B (es) | Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos. | |
| WO2010011999A3 (en) | Methods and compositions for eliciting an amyloid-selective immune response | |
| ATE526345T1 (de) | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit | |
| WO2006116442A3 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| WO2005103713A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| MA55282A (fr) | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf | |
| KR20090058497A (ko) | 프리온 단백질에 대한 신규의 항체 및 그 용도 | |
| MA55284A (fr) | Procédés de production de compositions d'anticorps anti-tnf | |
| Dornieden et al. | Characterization of a single-chain variable fragment recognizing a linear epitope of Aβ: a biotechnical tool for studies on Alzheimer’s disease? | |
| CA3080263A1 (en) | Method for diagnosing cancer from blood |